|
|
|
|
Vol. 57, Issue 1, 144-152, January 2000
Molecular Neuropharmacology Section, Experimental Therapeutics
Branch, National Institute of Neurological Disorders and Stroke,
National Institutes of Health, Bethesda, Maryland
The molecular determinants that govern selective ligand binding to the
rat D4 dopamine receptor were investigated by substituting D2 dopamine receptor sequences into a D4
dopamine receptor background. The resulting mutant D4
dopamine receptors were then screened with a panel of 10 selective and
nonselective ligands, which included two allosteric modulators as
sensitive measures of protein conformational changes. Mutation of a
phenylalanine at position 88 in the second transmembrane-spanning
domain (TMS2) of the D4 receptor to the corresponding
valine in the D2 receptor D4-F88V resulted in
an ~100-fold decrease in the affinity of the highly
D4-selective drug 3-{[4-(4-iodophenyl)
piperazin-1-yl]methyl}-1H-pyrrolo[2,3-b]pyridine (L-750,667)
without substantially affecting the binding of the other ligands.
Mutations at the extracellular side of D4-TMS3 produced
moderate decreases in L-750,667 binding affinities with concomitant
increases in binding affinity for the
D2/D3-selective antagonist (
)-raclopride.
However, the binding affinities of these same D4-TMS3
mutants for the allosteric modulator isomethylbutylamiloride also were
an anomalous 6- to 20-fold higher than either wild-type receptor. In
the combined D4-F88V/TMS3 mutants, L-750,667 binding affinity was further decreased, but this decrease was not additive. More importantly, the combined D4-F88V/TMS3 mutants had
(
)-raclopride and isomethylbutylamiloride binding properties that
reverted back to those of the wild-type D4-receptor. In
contrast to the D4-F88V mutant, the adjacent
D4-L87W mutant had an increased affinity for ligands with
extended structures, but had essentially no effect on ligands with
compact structures. These findings demonstrate that two residues near
the extracellular side of D4-TMS2 are critical molecular
determinants for the selective binding of L-750,667 and ligands with
extended structures.
This article has been cited by other articles:
![]() |
G. Lebon, C. J. Langmead, B. G. Tehan, and E. C. Hulme Mutagenic Mapping Suggests a Novel Binding Mode for Selective Agonists of M1 Muscarinic Acetylcholine Receptors Mol. Pharmacol., February 1, 2009; 75(2): 331 - 341. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Ericksen, D. F. Cummings, H. Weinstein, and J. A. Schetz Ligand Selectivity of D2 Dopamine Receptors Is Modulated by Changes in Local Dynamics Produced by Sodium Binding J. Pharmacol. Exp. Ther., January 1, 2009; 328(1): 40 - 54. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Al-Fulaij, Y. Ren, M. Beinborn, and A. S. Kopin Identification of Amino Acid Determinants of Dopamine 2 Receptor Synthetic Agonist Function J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 298 - 307. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kortagere, P. Gmeiner, H. Weinstein, and J. A. Schetz Certain 1,4-Disubstituted Aromatic Piperidines and Piperazines with Extreme Selectivity for the Dopamine D4 Receptor Interact with a Common Receptor Microdomain Mol. Pharmacol., December 1, 2004; 66(6): 1491 - 1499. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. R. Hollon, M. J. Bek, J. E. Lachowicz, M. A. Ariano, E. Mezey, R. Ramachandran, S. R. Wersinger, P. Soares-da-Silva, Z. F. Liu, A. Grinberg, et al. Mice Lacking D5 Dopamine Receptors Have Increased Sympathetic Tone and Are Hypertensive J. Neurosci., December 15, 2002; 22(24): 10801 - 10810. [Abstract] [Full Text] [PDF] |
||||